Asia-Pacific Cervical Cancer Diagnostic Market – Industry Trends and Forecast to 2030

Asia-Pacific Cervical Cancer Diagnostic Market Analysis and Insights  

The Asia-Pacific cervical cancer diagnostic market is growing in the forecast year due to the rise in market players and the availability of various cervical cancer diagnostic products and brands. Along with this, market players are engaged in advanced cervical cancer diagnostics. The rising prevalence of cervical cancer is further expected to boost market growth. However, the stringent rules and regulations may restrain market growth in the forecast period. The various government and private collaborations, increasing R&D activities, and strategic initiatives by market players are giving opportunities to the market. However, false results in cervical cancer screening tests are projected to be a key challenge to market growth.

The Asia-Pacific cervical cancer diagnostic market is expected to gain market growth in the forecast period of 2023 to 2030. Data Bridge Market Research analyses that the market is growing with a CAGR of 8.0% in the forecast period of 2023 to 2030 and is expected to reach USD 2,727.41 million by 2030.

Market Definition:

Cervical cancer is a type of cancer that develops in the cervix of the female reproductive tract. It is becoming more prevalent as the number of HPV-infected patients increases, and there is a greater emphasis on early detection and treatment, which is expected to accelerate the development of cervical cancer diagnosis. Increasing government investment in raising awareness about early cancer detection and increasing healthcare spending would also propel business growth. The most common cause of cervical cancer is HPV (Human Papillomavirus) infection. Other lifestyle choices that can raise the risk include smoking, drinking, a diet low in fruits, and vegetables, taking birth control pills, and teenage sexual encounters. Since, cervical cancer is treatable once diagnosed in an early stage, women at risk of developing the disease must undergo routine testing to identify the disease early, allowing the market to expand.

Asia-Pacific Cervical Cancer Diagnostic Market Dynamics

This section deals with understanding the market drivers, opportunities, restraints, and challenges. All of this is discussed in detail below:

Drivers

• Rising awareness of the early diagnosis of cervical cancer

There is an enormous range of risk factors being reported for cervical cancer. Therefore awareness about its diagnosis has increased in recent years. Various diagnostic tests are available, such as PAP (Papanicolaou) testing, human papillomavirus testing, colposcopy, cervical biopsies, and cystoscopy among others. Hence, to reduce the risk factors, early diagnosis is very important.

• Increasing prevalence and incidence of cervical cancer

Cervical cancer is a type of cancer that develops in the female reproductive tract's cervix. The irregular development of cancer cells in the cervix tissue frequently defines cervical cancer. Adenocarcinoma or squamous cell carcinoma can develop from cervical cancer. The most common cause of cervical cancer is HPV (Human Papillomavirus) infection. Cervical cancer is classified into two types' adenocarcinoma and squamous cell carcinoma. Cervical cancer is diagnosed using a variety of advanced laboratory tests, tools, and procedures that evaluate abnormal cells and strains of the human papillomavirus (HPV).

Opportunities

• Rising healthcare expenditure

Healthcare expenditure has increased worldwide as people's disposable income in various countries increases. Moreover, to accomplish the population requirements, government bodies and healthcare organizations are taking the initiative to accelerate healthcare expenditure. The rise in healthcare expenditure simultaneously helps healthcare settings to improve their treatment facilities on cervical cancer diagnostic as the disorder has been highly prevalent in recent years.

Also, the strategic initiatives key market players take will provide structural integrity and future opportunities for the Asia-Pacific cervical cancer diagnostic market in the forecast period.

Restraints/Challenges

However, cervical cancer diagnostic drugs may have adverse side effects; it is challenging to balance the risks with the benefits of treatment due to the increasing side effects of cancer medication hampering the market demand.

Moreover, increasing approvals of HPV vaccines by regulatory authorities are expected to hinder the growth of the Asia-Pacific cervical cancer diagnostic market. These developments are rapidly happening across the globe to reduce the cases of cervical cancer, which can be a restraining factor for the market.

The use of various treatment drugs across the globe is rapidly increasing, and with the increasing prevalence of cervical cancer, there is a need for timely diagnosis and treatment. At the same time, the players of the cervical cancer diagnostic manufacturers in the market have to follow certain regulations to get approval from the upper authorities for launching the product in the market. These stringent guidelines need to be followed; this is one of the most difficult tasks of all the steps. The pre-market approval of various medical drugs varies from one country to another.

Recent Development

• In August 2020, Siemens Healthcare GmbH agreed with Varian Medical Systems, Inc. for acquisition; with this acquisition, Siemens Healthcare has helped develop advanced solutions to treat cancer and strengthen its position in the healthcare industry

Asia-Pacific Cervical Cancer Diagnostic Market Scope

The Asia-Pacific cervical cancer diagnostic market is segmented into product type, age group, stages, end users, and distribution channel. The growth amongst these segments will help you analyse meagre growth segments in the industries and provide the users with a valuable market overview and market insights to make strategic decisions to identify core market applications.

Product Type

• Imaging Test
• Screening Test
• Visual Examination
• Cervical Biopsies
• Other Procedures

On the basis of product type, the Asia-Pacific cervical cancer diagnostic market is segmented into imaging test, screening test, visual examination, cervical biopsies, and other procedures.

Age Group

• Below 21
• 21-29
• 30-65
• 65 and Above

On the basis of age group, the Asia-Pacific cervical cancer diagnostic market is segmented into below 21, 21-29, 30-65, and 65 and above.

Stages

• Stage I
• Stage II
• Stage III
• Stage IV

On the basis of stage, the Asia-Pacific cervical cancer diagnostic market is segmented into stage I, stage II, stage III, and stage IV.

End Users

• Cancer And Radiation Therapy Centers
• Hospitals
• Specialty Clinics
• Cancer Research Organization
• Diagnostic Laboratories
• Community Health Centers

On the basis of end users, the Asia-Pacific cervical cancer diagnostic market is segmented into hospitals, diagnostic laboratories, specialty clinics, community health centers, cancer research organization, and cancer and radiation therapy centers.

Distribution Channel

• Direct Tender
• Retail Sales
• Online Sales

On the basis of distribution channel, the Asia-Pacific cervical cancer diagnostic market is segmented into direct tender, retail sales, and online sales.

Cervical Cancer Diagnostic Market Regional Analysis/Insights 

The Asia-Pacific cervical cancer diagnostic market is analysed, and market size insights and trends are provided by country, product type, age group, stages, end users, and distribution channel as referenced above.

Some countries covered in the Asia-Pacific region are China, Japan, India, South Korea, Australia, Singapore, Thailand, Malaysia, Indonesia, Philippines and Rest of Asia-Pacific.

China is expected to dominate the Asia-Pacific cervical cancer diagnostic market in terms of market share and market revenue and will continue to flourish its dominance during the forecast period. This is due to the increasing prevalence of cervical cancer in the Asia-Pacific region.

The country section of the report also provides individual market-impacting factors and changes in regulations in the market that impact the current and future trends of the market. Data points, such as new and replacement sales, country demographics, disease epidemiology, and import-export tariffs, are some of the major pointers used to forecast the market scenario for individual countries. In addition, the presence and availability of Asia-Pacific brands, their challenges faced due to high competition from local and domestic brands, and the impact of sales channels are considered while providing forecast analysis of the country data.

Competitive Landscape and Asia-Pacific Cervical Cancer Diagnostic Market Share Analysis

The Asia-Pacific cervical cancer diagnostic market competitive landscape provides details of the competitors. Details include company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, Asia-Pacific presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, and application dominance. The above data points are only related to the companies focusing on the Asia-Pacific cervical cancer diagnostic market.

Some of the major players operating in the Asia-Pacific cervical cancer diagnostic market are Siemens Healthcare GmbH, BD, F. Hoffmann-La Roche Ltd, Abbott, Hologic, Inc., Quest Diagnostics Incorporated, Bio-Rad Laboratories, Inc., QIAGEN, The Cooper Companies Inc., Seegene Inc., Sysmex Corporation, MobileODT, Zilico, Jiangsu Mole Bioscience Co. Ltd., Guided Therapeutics, Inc., GenomeMe Lab Inc., Arbor Vita Corporation, and LCM GENECT Srl among others.

SKU-69542